Triumph Capital Management Has $413,000 Stake in Teladoc Health, Inc. (NYSE:TDOC)

Triumph Capital Management boosted its holdings in shares of Teladoc Health, Inc. (NYSE:TDOC) by 11.4% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 19,154 shares of the health services provider’s stock after buying an additional 1,956 shares during the quarter. Triumph Capital Management’s holdings in Teladoc Health were worth $413,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Hexagon Capital Partners LLC boosted its holdings in Teladoc Health by 204.4% during the fourth quarter. Hexagon Capital Partners LLC now owns 1,586 shares of the health services provider’s stock valued at $34,000 after acquiring an additional 1,065 shares during the period. RIA Advisory Group LLC bought a new stake in shares of Teladoc Health in the fourth quarter valued at about $36,000. GAMMA Investing LLC bought a new stake in shares of Teladoc Health in the fourth quarter valued at about $41,000. Byrne Asset Management LLC bought a new stake in shares of Teladoc Health in the third quarter valued at about $60,000. Finally, Van ECK Associates Corp lifted its stake in shares of Teladoc Health by 20.3% in the fourth quarter. Van ECK Associates Corp now owns 3,589 shares of the health services provider’s stock valued at $77,000 after buying an additional 606 shares during the period. 76.82% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

TDOC has been the subject of a number of analyst reports. Royal Bank of Canada cut their price target on shares of Teladoc Health from $25.00 to $18.00 and set an “outperform” rating for the company in a research note on Friday, April 26th. Truist Financial cut their price target on shares of Teladoc Health from $23.00 to $17.00 and set a “hold” rating for the company in a research note on Wednesday, March 6th. Oppenheimer cut their price target on shares of Teladoc Health from $26.00 to $21.00 and set an “outperform” rating for the company in a research note on Friday, April 26th. Stifel Nicolaus cut their price target on shares of Teladoc Health from $21.00 to $16.00 and set a “hold” rating for the company in a research note on Friday, April 26th. Finally, Piper Sandler cut their price target on shares of Teladoc Health from $30.00 to $25.00 and set an “overweight” rating for the company in a research note on Wednesday, February 21st. Twelve analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $18.73.

Insider Activity at Teladoc Health

In related news, CEO Jason N. Gorevic sold 53,755 shares of the business’s stock in a transaction on Monday, March 4th. The shares were sold at an average price of $14.52, for a total value of $780,522.60. Following the sale, the chief executive officer now directly owns 653,073 shares of the company’s stock, valued at approximately $9,482,619.96. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, CEO Jason N. Gorevic sold 53,755 shares of the business’s stock in a transaction on Monday, March 4th. The shares were sold at an average price of $14.52, for a total value of $780,522.60. Following the sale, the chief executive officer now directly owns 653,073 shares of the company’s stock, valued at approximately $9,482,619.96. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Andrew Turitz sold 6,190 shares of Teladoc Health stock in a transaction on Monday, March 4th. The shares were sold at an average price of $14.52, for a total transaction of $89,878.80. Following the completion of the sale, the executive vice president now owns 39,429 shares in the company, valued at $572,509.08. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 135,441 shares of company stock valued at $2,038,251. 0.95% of the stock is owned by corporate insiders.

Teladoc Health Trading Up 0.4 %

Shares of NYSE TDOC opened at $12.81 on Thursday. The company’s fifty day moving average is $14.48 and its 200-day moving average is $17.60. The stock has a market cap of $2.17 billion, a price-to-earnings ratio of -9.08 and a beta of 0.97. Teladoc Health, Inc. has a twelve month low of $12.53 and a twelve month high of $30.41. The company has a quick ratio of 3.47, a current ratio of 3.82 and a debt-to-equity ratio of 0.67.

Teladoc Health (NYSE:TDOC) last announced its quarterly earnings results on Thursday, April 25th. The health services provider reported ($0.49) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.02). The firm had revenue of $646.13 million for the quarter, compared to the consensus estimate of $637.31 million. Teladoc Health had a negative return on equity of 10.13% and a negative net margin of 8.90%. The company’s revenue for the quarter was up 2.7% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.37) earnings per share. Equities research analysts predict that Teladoc Health, Inc. will post -1.04 EPS for the current year.

About Teladoc Health

Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.